Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
August 02 2021 - 8:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2021
Commission
file number: 001-40231
Universe
Pharmaceuticals INC
265
Jingjiu Avenue
Jinggangshan
Economic and Technological Development Zone
Ji’an,
Jiangxi, China 343100
+86-0796-8403309
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Explanatory
Note:
Universe
Pharmaceuticals INC (the “Company”) is filing this report on Form 6-K to report its financial results for the six months
ended March 31, 2021 and to discuss its recent corporate developments.
SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements
in this current report with respect to the Company’s current plans, estimates, strategies and beliefs and other statements that
are not historical facts are forward-looking statements about the future performance of the Company. Forward-looking statements include,
but are not limited to, those statements using words such as “believe,” “expect,” “plans,” “strategy,”
“prospects,” “forecast,” “estimate,” “project,” “anticipate,” “aim,”
“intend,” “seek,” “may,” “might,” “could” or “should,” and words
of similar meaning in connection with a discussion of future operations, financial performance, events or conditions. From time to time,
oral or written forward-looking statements may also be included in other materials released to the public. These statements are based
on management’s assumptions, judgments and beliefs in light of the information currently available to it. The Company cautions
investors that a number of important risks and uncertainties could cause actual results to differ materially from those discussed in
the forward-looking statements, including but not limited to, product and service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with
the Securities and Exchange Commission. Therefore, investors should not place undue reliance on such forward-looking statements. Actual
results may differ significantly from those set forth in the forward-looking statements.
All
such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by
the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company
disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
EXHIBIT
INDEX
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
Universe
Pharmaceuticals INC.
|
|
|
Date:
August 2, 2021
|
By:
|
/s/
Gang Lai
|
|
|
Gang
Lai
|
|
|
Chief
Executive Officer
|
4
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Jul 2023 to Jul 2024